SOUTH SAN FRANCISCO, Calif., June 15, 2019 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of ...
SAN DIEGO & SHANGHAI, January 07, 2025--(BUSINESS WIRE)--Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation ...
Kyung-Ah Kim, President & CEO of Samsung Bioepis (left) and Zhaoyuan ‘Tony’ Chen, Founder and CEO of Phrontline Biopharma (right) have signed a global strategic partnership agreement to advance ...
-- Company Doses First Participants in Phase 2 Portion of Ongoing VAX-31 Phase 1/2 Study in Adults Following Independent Review of Phase 1 Safety and Tolerability Data; Topline Safety, Tolerability ...
BioWorld - Saturday, September 20, 2025 Breaking News: Trump administration impacts continue to roil the life sciences sector See today's BioWorld Science Home » First-in-class drug-Fc conjugate shows ...
NaPi2b is a sodium-dependent phosphate transporter that is mainly responsible for phosphate homeostasis in humans. Overexpression of NaPi2b has been associated with several types of cancers such as ...
SUZHOU, China, April 18, 2022 /PRNewswire/ -- GeneQuantum Healthcare (Suzhou) Co., Ltd., a company specializing in site-specific bioconjugation for next generation biotherapeutics, has signed an ...
"GeneQuantum was founded with the goal of addressing critical unmet needs in global healthcare through the development of innovative technologies. GQ1010 highlights its best-in-class potential through ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback